Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CK Life Sciences International (Holdings), Inc. ( (HK:0775) ) has issued an update.
CK Life Sciences has reported a positive interim clinical update from its majority-owned subsidiary Dogwood Therapeutics, which is running a Phase 2b trial of Halneuron® for chemotherapy-induced neuropathic pain (CINP). An independent statistical review of data from 97 treated patients indicated that Halneuron® is showing a separation from placebo in pain improvement over a four-week period, with the patient group characterized by long-standing CINP and widespread concurrent use of other chronic pain medications. Dogwood also highlighted a notably low dropout rate of about 4.4%, which appears favourable compared with existing FDA-approved chronic pain drugs and supports Halneuron®’s safety and tolerability profile seen in earlier trials. Top-line Phase 2b results are expected in the third quarter of 2026, and while this could strengthen CK Life Sciences’ position in neuropathic pain therapeutics if confirmed and ultimately approved, the company cautions that Halneuron® remains at the mid-stage clinical trial phase with outcomes still subject to further regulatory review and uncertainty for shareholders and potential investors.
The most recent analyst rating on (HK:0775) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on CK Life Sciences International (Holdings), Inc. stock, see the HK:0775 Stock Forecast page.
More about CK Life Sciences International (Holdings), Inc.
CK Life Sciences International (Holdings) Inc. is a Hong Kong–listed life sciences company with a strategic focus on biopharmaceutical investments, including an approximately 83% indirect stake in Dogwood Therapeutics, a Nasdaq-listed, development-stage biopharmaceutical firm developing new medicines for pain and neuropathic disorders.
Average Trading Volume: 7,469,427
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.98B
See more insights into 0775 stock on TipRanks’ Stock Analysis page.